Developer docs
API playgroundTry for free, no card

Search company profiles

Limula

Full company profile

uuid0000fx8

Namestring
Limula
Legal namestring
Limula SA
Websiteurl
limula.ch
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Limula SA is a Swiss cell and gene therapy manufacturing technology company founded in 2020 and headquartered at Biopôle in Lausanne, with operations spanning Switzerland, Italy, Portugal, and France. The company develops automated, closed-system hardware that combines a bioreactor and a centrifuge inside a single vessel, eliminating the cell transfers between devices that characterize conventional cell therapy workflows. This "one-pot" architecture sequences incubation, centrifugation, and volume management without open human intervention, supporting scalable volumes from 2 mL to 400 mL and diverse modalities including CAR-T, hematopoietic stem cells, NK cells, and TILs. A U.S. patent covering the integration method was granted in May 2025.

The commercial product portfolio consists of LimGROW, a research-tier platform for process development, and LimONE, a clinical/commercial platform unveiled in March 2025 for GMP-grade end-to-end cell therapy manufacturing. Both products share the same core consumable, eliminating re-engineering when customers transition from research to clinical production. Limula's revenue model centers on device sales paired with single-use consumables, supplemented by a Technology Access Program that places functional prototypes with selected biotech, hospital, and CDMO partners. Pricing is not publicly disclosed; first commercial revenues were generated in early 2026 from engagements with eight biotech companies and clinical centers, following the company's transition from development to commercial phase under incoming CEO Thomas Eaton.

Limula targets three primary customer segments: biotech and biopharma developers of autologous and allogeneic cell therapies, hospitals and clinical cell therapy centers performing stem cell transplantation and point-of-care manufacturing, and contract development and manufacturing organizations (CDMOs). Named end-users and partners include San Raffaele Telethon Institute for Gene Therapy (Italy), Institut Paoli-Calmettes (France, 150+ annual transplants), Stemmatters (Portugal), University of Geneva, University of Fribourg, and Bracco Imaging. The company is venture-backed (CHF 6.2M seed led by LifeX Ventures, May 2024) and supported by substantial non-dilutive funding including EIC Pathfinder (€4.7M), Innosuisse (CHF 2.5M Accelerator), and FIT grants, with headcount stated at 1-10 employees as of the most recent disclosure.

Short descriptiontext

Limula SA is a Swiss medtech company that automates cell and gene therapy manufacturing via LimONE, a closed single-vessel platform combining bioreactor and centrifuge. It serves biotech developers, hospitals, and CDMOs producing CAR-T, HSC, NK, and TIL therapies, and began generating first commercial revenues in early 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, bioreactor technology, automated cell processing, cell and gene therapy, bioprocess automation
Industry2 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing33911
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy Manufacturing Equipment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Automated cell therapy manufacturing devices and consumables
TypeHardware Sales
Description

Limula sells its LimONE automated manufacturing platform and associated single-use consumables to cell therapy developers, CDMOs, and hospitals. The platform is designed for GMP-compliant clinical-grade production.

limula.ch
2Technology access and pilot programs
TypeProfessional Services
Description

Early access program providing selected partners access to the technology for pilot testing and process development, generating first commercial revenues starting early 2026 through engagements with eight biotech companies and clinical centers.

bioalps.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LimGROW
Description

Research-appropriate implementation of Limula's technology for process development, empowering users to develop, optimise, and derisk process steps that require incubation.

limula.ch
+1 more record
Core offering1 text field

Limula provides a unified platform for cell and gene therapy manufacturing that combines a bioreactor and a centrifuge into a single closed vessel, enabling both cell incubation and in-situ centrifugation without cell transfers. Its two main products, LimGROW (for process development and research) and LimONE (for clinical-grade commercial manufacturing), use the same core technology and consumable so protocols transfer seamlessly from R&D to GMP production of CAR-T, hematopoietic stem cells (HSCs), NK cells, and other ATMPs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 40-fold cell expansion achieved in first fully automated CAR-T production run, outperforming current gold-standard solutions
+5 more records
Product overview1 text field

Limula provides a unified platform for cell and gene therapy manufacturing across scales. The company offers two main products: LimGROW and LimONE. LimGROW is a research-appropriate implementation designed for process development and optimization, while LimONE is the commercial-scale platform for clinical-grade production. Both products share the same core technology that combines a bioreactor and centrifuge into a single vessel, enabling seamless technology transfer from research to commercial production without process changes.

Product and service2 records
1LimGROW
CategoryCell therapy process development equipment
Description

LimGROW is a research-appropriate implementation of Limula's bioreactor-centrifuge technology, designed for process development. It enables cell therapy developers to develop, optimize, and derisk incubation-requiring process steps before implementing full automation on the clinical platform.

2LimONE
CategoryAutomated cell therapy manufacturing platform
Description

LimONE is Limula's clinical-grade manufacturing platform that combines a mechatronic hardware device, single-use consumable, and software suite to deliver fully automated, closed, end-to-end production of CAR-T, gene-edited HSCs, and other cell therapies. It supports scalable volumes from 2 mL to 400 mL and was used to complete a 7-day fully automated CAR-T run with over 40-fold cell expansion.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Global pharmaceutical company in diagnostic imaging, expanding into cell therapy manufacturing. Innosuisse-funded R&D project with Limula and University of Fribourg to combine lipid-based microbubble technology with Limula's automated processing for bead-free cell selection and activation. Goal is to reduce costs and improve treatment quality.

2University of Fribourg (Prof. Nicola Vannini)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Innosuisse-funded collaboration with Bracco and Limula to develop automated cell selection alternative using microbubbles. Prof. Vannini contributes expertise in T-cell physiology and metabolism to evaluate impact on cell product fitness.

limula.ch
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-15
Description

Leading cancer comprehensive centre in Marseille, France, performing over 150 stem cell transplants annually. Collaboration to adopt LimONE for autologous HSC transplantation, focusing on cryoprotectant removal and cell debris washing. Dr. Boris Calmel, Head of Manufacturing at IPC Cell Therapy Center, provides external validation of technology differentiation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-15
Description

World-recognized centre of excellence in Milan for research and clinical translation of cell and gene therapy. Partnership to explore novel bioreactor for expansion of hematopoietic stem cells, building on SR-Tiget's expertise in HSC-based gene therapy (developed Strimvelis and Libmeldy). Initiated under EIC Pathfinder Cell and Gene Therapy Sub Portfolio.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-02-03
Description

Swiss technology innovation center supported Limula in moving technology from prototype to pre-industrial stage. Innosuisse-funded project to find most suitable manufacturing process for large-scale industrial production while preserving functionalities. Resulted in pre-industrial solution used by Limula and partners for cell therapy production testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Innosuisse-funded project to develop non-viral gene transfer technology for next-generation CAR-T cell therapies. Prof. Migliorini leads Brain Tumour and Immune Cell Engineering Group (BTICE) at AGORA Cancer Research Centre. Published peer-reviewed article on magnetic bead-sensitized optoporation for mRNA CAR-T in 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-15
Description

Portuguese CDMO providing expertise in Quality by Design of cell therapy process development and cGMP manufacturing. Partner in Eurostars grant (EUR 1.14M) and EIC PAT4CGT project. Received first LimONE device installation in June 2025 for training and GMP operations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-04-15
Description

Swiss company developing C-NETICS automated system for continuously monitoring cell density and viability. Partner in Eurostars grant to integrate on-line and real-time cell analytics module into Limula's bioreactor technology for end-to-end CAR-T production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deeptech accelerator based in France coordinating the PAT4CGT consortium. Provides research and innovation support services. Synthetic Biology Practice Leader Nadège Grabowski contributed to EIC project evaluation.

Strategic tierCoreTypeTechnology or Integration
Description

Spin-off of University of Freiburg, Germany, bringing expertise in miniature biosensors and micro control systems for PAT4CGT project.

11Technische Universität Wien (Prof. Christoph Herwig)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Bioprocess Technology research group contributes to development of digital twins and predictive algorithms for PAT4CGT project.

limula.ch
12Exothera
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Belgian company offering development and manufacturing services for viral vectors, providing end-user inputs and in-depth assessment of resulting PAT4CGT solution.

limula.ch
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Stockholm-based industrial design firm that partnered with Limula to incorporate input from over 20 academic and industry experts into key design choices for LimONE following in-person feedback sessions in Lausanne.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cellares offers the Cell Shuttle, an automated cell therapy manufacturing platform targeting large-scale GMP production. It competes head-to-head with LimONE for biotech and CDMO accounts and represents one of the best-capitalized automation startups (>$250M raised) pursuing the same end-to-end cell therapy manufacturing vision.

TypeBroad incumbent
Description

Lonza is a global CDMO and bioprocess technology provider offering the Cocoon platform for automated cell therapy manufacturing. As both a CDMO service provider and equipment supplier, Lonza competes with Limula across both equipment sales and manufacturing services, with significantly greater scale and commercial reach.

TypeDirect peer
Description

Cytiva (formerly GE Healthcare Life Sciences, owner of Sepax and Sefia systems) provides automated cell processing platforms widely used in biobanks, transplant centers, and cell therapy manufacturing. Limula's Head of Operations Olivier Waridel previously led Biosafe Group, the Sepax originator, before its acquisition by GE. Sepax is a direct competitor to LimONE's in-situ centrifugation approach.

TypeBroad incumbent
Description

Terumo BCT (now part of Terumo) offers the Quantum cell expansion system for cell and gene therapy manufacturing. It serves hospital and biopharma customers with automated, closed cell processing capabilities and competes with Limula in cell therapy manufacturing automation.

TypeBroad incumbent
Description

Sartorius provides upstream and downstream bioprocessing equipment and consumables used across cell therapy manufacturing workflows. While not a direct cell therapy platform competitor, Sartorius competes for the same bioprocessing budgets and is increasingly offering integrated cell therapy manufacturing solutions.

TypeEmerging player
Description

Multiply Labs develops robotic cell therapy manufacturing systems that automate the production of cell therapies using industrial robotics. As an early-stage company, it overlaps with Limula in targeting automation of CAR-T and other cell therapy manufacturing for biotech and CDMO customers.

TypeDirect peer
Description

Ori Biotech's IRO platform is designed to automate and scale cell and gene therapy manufacturing with a closed, GMP-compliant system. It is a direct competitor targeting the same biotech and CDMO customer segments as Limula and offers similar throughput and process-control benefits.

TypeBroad incumbent
Description

Thermo Fisher Scientific offers cell therapy manufacturing solutions through its bioproduction and pharma services businesses, including cell processing equipment, consumables, and contract manufacturing services. It competes broadly with Limula across the cell therapy manufacturing value chain and has substantially greater commercial and R&D resources.

TypeDirect peer
Description

Miltenyi Biotec's Prodigy platform is one of the most widely adopted automated cell therapy manufacturing systems. It directly competes with LimONE in autologous and allogeneic cell processing for CAR-T, HSC, and other cell therapies, and represents the entrenched incumbent Limula must displace in hospital and CDMO accounts.

TypeRegional player
Description

Stemmatters is a Portuguese CDMO specializing in cell therapy manufacturing that has partnered with Limula in the PAT4CGT consortium and is an early LimONE installation site. While primarily a service provider rather than a direct equipment competitor, Stemmatters represents an important channel and reference customer in the European market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Limula

Cell Therapy Manufacturing Equipmentlimula.ch

Limula SA is a Swiss medtech company that automates cell and gene therapy manufacturing via LimONE, a closed single-vessel platform combining bioreactor and centrifuge. It serves biotech developers, hospitals, and CDMOs producing CAR-T, HSC, NK, and TIL therapies, and began generating first commercial revenues in early 2026.

What Limula does

Limula SA is a Swiss cell and gene therapy manufacturing technology company founded in 2020 and headquartered at Biopôle in Lausanne, with operations spanning Switzerland, Italy, Portugal, and France. The company develops automated, closed-system hardware that combines a bioreactor and a centrifuge inside a single vessel, eliminating the cell transfers between devices that characterize conventional cell therapy workflows. This "one-pot" architecture sequences incubation, centrifugation, and volume management without open human intervention, supporting scalable volumes from 2 mL to 400 mL and diverse modalities including CAR-T, hematopoietic stem cells, NK cells, and TILs. A U.S. patent covering the integration method was granted in May 2025.

The commercial product portfolio consists of LimGROW, a research-tier platform for process development, and LimONE, a clinical/commercial platform unveiled in March 2025 for GMP-grade end-to-end cell therapy manufacturing. Both products share the same core consumable, eliminating re-engineering when customers transition from research to clinical production. Limula's revenue model centers on device sales paired with single-use consumables, supplemented by a Technology Access Program that places functional prototypes with selected biotech, hospital, and CDMO partners. Pricing is not publicly disclosed; first commercial revenues were generated in early 2026 from engagements with eight biotech companies and clinical centers, following the company's transition from development to commercial phase under incoming CEO Thomas Eaton.

Limula targets three primary customer segments: biotech and biopharma developers of autologous and allogeneic cell therapies, hospitals and clinical cell therapy centers performing stem cell transplantation and point-of-care manufacturing, and contract development and manufacturing organizations (CDMOs). Named end-users and partners include San Raffaele Telethon Institute for Gene Therapy (Italy), Institut Paoli-Calmettes (France, 150+ annual transplants), Stemmatters (Portugal), University of Geneva, University of Fribourg, and Bracco Imaging. The company is venture-backed (CHF 6.2M seed led by LifeX Ventures, May 2024) and supported by substantial non-dilutive funding including EIC Pathfinder (€4.7M), Innosuisse (CHF 2.5M Accelerator), and FIT grants, with headcount stated at 1-10 employees as of the most recent disclosure.

Limula firmographics

Firmographics
Name
Limula
Legal name
Limula SA
Website
https://limula.ch
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Limula SA is a Swiss medtech company that automates cell and gene therapy manufacturing via LimONE, a closed single-vessel platform combining bioreactor and centrifuge. It serves biotech developers, hospitals, and CDMOs producing CAR-T, HSC, NK, and TIL therapies, and began generating first commercial revenues in early 2026.
Ownership category
akta.pro rank

Limula industry classification

Industry
Product category
Cell Therapy Manufacturing Equipment
NAICS
Medical Equipment and Supplies Manufacturing (33911)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell therapy manufacturing
  • Bioreactor technology
  • Automated cell processing
  • Cell and gene therapy
  • Bioprocess automation

Where Limula is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Limula business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Automated cell therapy manufacturing devices and consumables: Limula sells its LimONE automated manufacturing platform and associated single-use consumables to cell therapy developers, CDMOs, and hospitals. The platform is designed for GMP-compliant clinical-grade production.
  2. Technology access and pilot programs: Early access program providing selected partners access to the technology for pilot testing and process development, generating first commercial revenues starting early 2026 through engagements with eight biotech companies and clinical centers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Limula product offering

Product offering

Core offering

Limula provides a unified platform for cell and gene therapy manufacturing that combines a bioreactor and a centrifuge into a single closed vessel, enabling both cell incubation and in-situ centrifugation without cell transfers. Its two main products, LimGROW (for process development and research) and LimONE (for clinical-grade commercial manufacturing), use the same core technology and consumable so protocols transfer seamlessly from R&D to GMP production of CAR-T, hematopoietic stem cells (HSCs), NK cells, and other ATMPs.

Product overview

Limula provides a unified platform for cell and gene therapy manufacturing across scales. The company offers two main products: LimGROW and LimONE. LimGROW is a research-appropriate implementation designed for process development and optimization, while LimONE is the commercial-scale platform for clinical-grade production. Both products share the same core technology that combines a bioreactor and centrifuge into a single vessel, enabling seamless technology transfer from research to commercial production without process changes.

Differentiator

Problem solved

Functional benefit

Brands

  • LimGROW: Research-appropriate implementation of Limula's technology for process development, empowering users to develop, optimise, and derisk process steps that require incubation.
  • LimONE

Products and services

  • LimGROW LimGROW is a research-appropriate implementation of Limula's bioreactor-centrifuge technology, designed for process development. It enables cell therapy developers to develop, optimize, and derisk incubation-requiring process steps before implementing full automation on the clinical platform.
  • LimONE LimONE is Limula's clinical-grade manufacturing platform that combines a mechatronic hardware device, single-use consumable, and software suite to deliver fully automated, closed, end-to-end production of CAR-T, gene-edited HSCs, and other cell therapies. It supports scalable volumes from 2 mL to 400 mL and was used to complete a 7-day fully automated CAR-T run with over 40-fold cell expansion.

Quantifiable outcome

  • Over 40-fold cell expansion achieved in first fully automated CAR-T production run, outperforming current gold-standard solutions
  • +5 more outcomes

Companies that use Limula

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Limula technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Limula partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Bracco ImagingcoreStrategic or Co-development Partner · 25 November 2025Global pharmaceutical company in diagnostic imaging, expanding into cell therapy manufacturing. Innosuisse-funded R&D project with Limula and University of Fribourg to combine lipid-based microbubble technology with Limula's automated processing for bead-free cell selection and activation. Goal is to reduce costs and improve treatment quality.
  • University of Fribourg (Prof. Nicola Vannini)coreStrategic or Co-development Partner · 25 November 2025Innosuisse-funded collaboration with Bracco and Limula to develop automated cell selection alternative using microbubbles. Prof. Vannini contributes expertise in T-cell physiology and metabolism to evaluate impact on cell product fitness.
  • Institut Paoli-Calmettes (IPC)coreStrategic or Co-development Partner · 15 September 2025Leading cancer comprehensive centre in Marseille, France, performing over 150 stem cell transplants annually. Collaboration to adopt LimONE for autologous HSC transplantation, focusing on cryoprotectant removal and cell debris washing. Dr. Boris Calmel, Head of Manufacturing at IPC Cell Therapy Center, provides external validation of technology differentiation.
  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)coreStrategic or Co-development Partner · 15 March 2024World-recognized centre of excellence in Milan for research and clinical translation of cell and gene therapy. Partnership to explore novel bioreactor for expansion of hematopoietic stem cells, building on SR-Tiget's expertise in HSC-based gene therapy (developed Strimvelis and Libmeldy). Initiated under EIC Pathfinder Cell and Gene Therapy Sub Portfolio.
  • CSEMcoreImplementation/ SI/ Consulting Partner · 3 February 2023Swiss technology innovation center supported Limula in moving technology from prototype to pre-industrial stage. Innosuisse-funded project to find most suitable manufacturing process for large-scale industrial production while preserving functionalities. Resulted in pre-industrial solution used by Limula and partners for cell therapy production testing.
  • University of Geneva (Prof. Denis Migliorini)coreStrategic or Co-development Partner · 1 December 2022Innosuisse-funded project to develop non-viral gene transfer technology for next-generation CAR-T cell therapies. Prof. Migliorini leads Brain Tumour and Immune Cell Engineering Group (BTICE) at AGORA Cancer Research Centre. Published peer-reviewed article on magnetic bead-sensitized optoporation for mRNA CAR-T in 2025.
  • StemmatterscoreStrategic or Co-development Partner · 15 April 2022Portuguese CDMO providing expertise in Quality by Design of cell therapy process development and cGMP manufacturing. Partner in Eurostars grant (EUR 1.14M) and EIC PAT4CGT project. Received first LimONE device installation in June 2025 for training and GMP operations.
  • CeidoscoreTechnology or Integration · 15 April 2022Swiss company developing C-NETICS automated system for continuously monitoring cell density and viability. Partner in Eurostars grant to integrate on-line and real-time cell analytics module into Limula's bioreactor technology for end-to-end CAR-T production.
  • Da Vinci LabscoreStrategic or Co-development PartnerDeeptech accelerator based in France coordinating the PAT4CGT consortium. Provides research and innovation support services. Synthetic Biology Practice Leader Nadège Grabowski contributed to EIC project evaluation.
  • Jobst TechnologiescoreTechnology or IntegrationSpin-off of University of Freiburg, Germany, bringing expertise in miniature biosensors and micro control systems for PAT4CGT project.
  • Technische Universität Wien (Prof. Christoph Herwig)minorStrategic or Co-development PartnerBioprocess Technology research group contributes to development of digital twins and predictive algorithms for PAT4CGT project.
  • ExotheraminorStrategic or Co-development PartnerBelgian company offering development and manufacturing services for viral vectors, providing end-user inputs and in-depth assessment of resulting PAT4CGT solution.
  • FjarylminorImplementation/ SI/ Consulting PartnerStockholm-based industrial design firm that partnered with Limula to incorporate input from over 20 academic and industry experts into key design choices for LimONE following in-person feedback sessions in Lausanne.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Limula competitors and assessment

Company assessment

Direct peers

  • Cellares: Cellares offers the Cell Shuttle, an automated cell therapy manufacturing platform targeting large-scale GMP production. It competes head-to-head with LimONE for biotech and CDMO accounts and represents one of the best-capitalized automation startups (>$250M raised) pursuing the same end-to-end cell therapy manufacturing vision.
  • Cytiva: Cytiva (formerly GE Healthcare Life Sciences, owner of Sepax and Sefia systems) provides automated cell processing platforms widely used in biobanks, transplant centers, and cell therapy manufacturing. Limula's Head of Operations Olivier Waridel previously led Biosafe Group, the Sepax originator, before its acquisition by GE. Sepax is a direct competitor to LimONE's in-situ centrifugation approach.
  • Ori Biotech: Ori Biotech's IRO platform is designed to automate and scale cell and gene therapy manufacturing with a closed, GMP-compliant system. It is a direct competitor targeting the same biotech and CDMO customer segments as Limula and offers similar throughput and process-control benefits.
  • Miltenyi Biotec: Miltenyi Biotec's Prodigy platform is one of the most widely adopted automated cell therapy manufacturing systems. It directly competes with LimONE in autologous and allogeneic cell processing for CAR-T, HSC, and other cell therapies, and represents the entrenched incumbent Limula must displace in hospital and CDMO accounts.

Broad incumbents

  • Lonza: Lonza is a global CDMO and bioprocess technology provider offering the Cocoon platform for automated cell therapy manufacturing. As both a CDMO service provider and equipment supplier, Lonza competes with Limula across both equipment sales and manufacturing services, with significantly greater scale and commercial reach.
  • Terumo BCT: Terumo BCT (now part of Terumo) offers the Quantum cell expansion system for cell and gene therapy manufacturing. It serves hospital and biopharma customers with automated, closed cell processing capabilities and competes with Limula in cell therapy manufacturing automation.
  • Sartorius: Sartorius provides upstream and downstream bioprocessing equipment and consumables used across cell therapy manufacturing workflows. While not a direct cell therapy platform competitor, Sartorius competes for the same bioprocessing budgets and is increasingly offering integrated cell therapy manufacturing solutions.
  • Thermo Fisher Scientific: Thermo Fisher Scientific offers cell therapy manufacturing solutions through its bioproduction and pharma services businesses, including cell processing equipment, consumables, and contract manufacturing services. It competes broadly with Limula across the cell therapy manufacturing value chain and has substantially greater commercial and R&D resources.

Emerging players

  • Multiply Labs: Multiply Labs develops robotic cell therapy manufacturing systems that automate the production of cell therapies using industrial robotics. As an early-stage company, it overlaps with Limula in targeting automation of CAR-T and other cell therapy manufacturing for biotech and CDMO customers.

Regional players

  • Stemmatters: Stemmatters is a Portuguese CDMO specializing in cell therapy manufacturing that has partnered with Limula in the PAT4CGT consortium and is an early LimONE installation site. While primarily a service provider rather than a direct equipment competitor, Stemmatters represents an important channel and reference customer in the European market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Limula social profiles

Digital presence

Limula financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Limula leadership team

Management profile

Number of profiles

Profiles11 records

Limula funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Limula M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Limula

What does Limula do?

Limula provides a unified platform for cell and gene therapy manufacturing that combines a bioreactor and a centrifuge into a single closed vessel, enabling both cell incubation and in-situ centrifugation without cell transfers. Its two main products, LimGROW (for process development and research) and LimONE (for clinical-grade commercial manufacturing), use the same core technology and consumable so protocols transfer seamlessly from R&D to GMP production of CAR-T, hematopoietic stem cells (HSCs), NK cells, and other ATMPs.

Is Limula a public or private company?

Limula is a private company. It is classified as venture growth investor backed and is currently operating.

When was Limula founded?

Limula was founded in 2020. It employs 1 to 10 people.

Where is Limula based?

Limula is headquartered in Epalinges, Switzerland, in the Europe region.

How does Limula make money?

Two revenue lines are on record. Automated cell therapy manufacturing devices and consumables are the primary driver. The others are technology access and pilot programs.

Who are Limula's main competitors?

Direct peers on record are Cellares, Cytiva, Ori Biotech and Miltenyi Biotec. Broad incumbents are Lonza, Terumo BCT, Sartorius and Thermo Fisher Scientific. Multiply Labs is listed as an emerging player. Stemmatters is listed as a regional player.

Does Limula have an API?

No public API is recorded for Limula.

What industry is Limula in?

Limula's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 33911 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioAlpsLimula Enters Commercial Phase of Its Cell Therapy PlatformVaud-based biotech company Limula has transitioned from a development-stage startup to a commercial entity, generating its first commercial revenues in early 2026 through engagements with eight biotech companies and clinical centers. The company completed its first fully automated, end-to-end 7-day CAR-T cell production run on its LimONE platform, achieving over 40-fold cell expansion with high transduction rates and cell viability exceeding current gold-standard solutions, with findings expected to be submitted for peer-reviewed publication. Co-founder Luc Henry has stepped down as CEO and been succeeded by Thomas Eaton as Limula enters its industrialization phase.startupticker.chLimula transitions to commercial phaseLimula, a Lausanne-based biotech startup, has completed the first fully automated, closed end-to-end CAR T-cell therapy production process on its LimONE device in 7 days, generating first revenues and establishing a growing customer pipeline of 8 biotech companies and clinical centers. The company also announced a leadership transition, with Thomas Eaton succeeding Luc Henry as CEO to guide the company through its commercial phase. The completed process achieved over 40-fold expansion with superior transduction rates and cell viability, outperforming current gold-standard solutions, with results to be submitted for peer review.GenengnewsIndustry-Academia Collaboration Formed to Improve Cell and Gene Therapy ManufacturingBracco Imaging and Limula have launched a collaborative R&D project with the University of Fribourg to develop automated manufacturing solutions for cell and gene therapies. Funded by an Innosuisse grant, the partnership aims to combine Bracco's lipid-based microbubble technology with Limula's automation tools to improve cell selection and processing efficiency.BioAlpsBracco, Limula and UNIFR Join Forces to Create Efficient Cancer Cell TherapiesBracco Imaging, Limula, and the University of Fribourg have formed a public-private partnership funded by Innosuisse with CHF 688,000 over two years to make cell and gene therapies like CAR-T treatments more accessible and affordable. The collaboration combines Bracco's lipid microbubble technology for cell isolation, Limula's automated cell therapy production device, and the University of Fribourg's expertise in T cell metabolism characterization. The partners aim to reduce the complexity and prohibitive costs of these therapies, which currently can reach several hundred thousand Swiss francs per dose, as the global market for such therapies is projected to exceed £80 billion by 2034.UtorontoMeet our startups — PRiME Next-Generation Precision MedicineMultiple Swiss biotech startups and innovation platforms are advancing in drug discovery, gene therapy, and cell processing technologies, with several focusing on precision medicine, AI-driven drug design, and personalized treatments. These companies include InVirtuo Laboratories SA, Limula, Go Healthy, Bionomous, and others, each developing next-generation therapeutics and research tools.BioAlpsLimula, Actival and AirCurve supported by the FITLimula, Actival, and AirCurve received Tech Loans from FIT: Limula got CHF 500,000 for building four cell-therapy prototypes, Actival received CHF 100,000 for dental aligner microchannel optimization, and AirCurve got CHF 100,000 for AI-guided robotic intubation materials. The loans aim to reduce costs and improve access to these technologies.startupticker.chLimula, Actival and AirCurve get FIT backingLimula, Actival, and AirCurve received FIT backing: Limula got a CHF 500,000 Tech Growth loan, while Actival and AirCurve each received a CHF 100,000 Tech Seed loan. Limula will build four prototypes for a 2025 test phase, Actival will optimize microchannel design, and AirCurve will refine its AI-guided robotic intubation system.PharmasourceLimula Secures $6.8M to Revolutionise Cell Therapy ManufacturingLimula has raised $6.8 million to advance its automated cell therapy manufacturing platform, aiming to improve accessibility to life-saving therapies. The oversubscribed seed round was led by LifeX Ventures, with numerous investors participating. Limula's novel bioreactor-centrifuge platform is designed to simplify and scale up production while meeting GMP requirements and reducing production risks.Manufacturing ChemistLimula raises $6.8M to enhance accessibility to cell and gene therapies with manufacturing platformLimula has raised $6.8 million in an oversubscribed seed round led by LifeX Ventures to advance its automated manufacturing platform for cell and gene therapies. The funding aims to scale the technology, which seeks to reduce costs and increase accessibility by automating complex manual processes currently limiting patient access to these treatments. Limula has also partnered with research centres like the San Raffaele Telethon Institute to test the platform ahead of commercial launch.